+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07405151

Study of Ifinatamab Deruxtecan Treatment in Advanced Esophageal Squamous Cell Carcinoma Participants with Previous Therapy

Led by Merck Sharp & Dohme LLC · Updated on 2026-10-02

60

Participants Needed

32

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating if ifinatamab deruxtecan I-DXd, an antibody-drug conjugate, can treat people with advanced esophageal squamous cell carcinoma ESCC who have not responded to previous treatments. The study aims to find out how many participants experience cancer shrinkage or disappearance after receiving I-DXd. This trial is a phase 2, open-label study focusing on participants with unresectable locally advanced or metastatic ESCC. Participants receive I-DXd through an intravenous infusion every 3 weeks. Treatment continues until the cancer progresses or other discontinuation criteria are met. The study includes a single group where all participants receive I-DXd. Rescue medications such as 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids may be given as needed according to approved guidelines. Throughout the study, participants are regularly monitored for tumor response, side effects, and overall health. Researchers assess the objective response rate up to about 14 months, as well as secondary outcomes including duration of response, progression-free survival, overall survival, and adverse events. The total study duration spans up to approximately 26 months, allowing for ongoing safety evaluations and follow-up.

CONDITIONS

Brief Title

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here